First National Bank of Omaha Takes Position in Edwards Lifesciences Corporation $EW

First National Bank of Omaha bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 41,118 shares of the medical research company’s stock, valued at approximately $3,720,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $266,000. NewEdge Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares in the last quarter. Sei Investments Co. grew its position in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its stake in Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after acquiring an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after acquiring an additional 1,065 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,570 shares of company stock valued at $2,219,390 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.4%

Shares of EW opened at $91.13 on Wednesday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $52.47 billion, a P/E ratio of 52.37, a PEG ratio of 2.30 and a beta of 0.85. The firm’s 50-day moving average is $88.90 and its two-hundred day moving average is $84.49.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the previous year, the business posted $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of several research reports. Truist Financial raised their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Citigroup lifted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.